Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 4 2Phase NA 1Phase 2/3 1

Status

Recruiting 3Not yet recruiting 2

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 84Breast Neoplasms 34Colorectal Neoplasms 26Lung Neoplasms 23Rectal Neoplasms 22Neoplasms 21Esophageal Squamous Cell Carcinoma 20Neoplasm Metastasis 19Esophageal Neoplasms 19Head and Neck Neoplasms 17Stomach Neoplasms 15Pancreatic Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Triple Negative Breast Neoplasms 12Small Cell Lung Carcinoma 12Ovarian Neoplasms 11Nasopharyngeal Carcinoma 10Carcinoma, Squamous Cell 10Recurrence 9Leukemia, Myeloid, Acute 9Colonic Neoplasms 9Uterine Cervical Neoplasms 8Prostatic Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma 7Glioblastoma 7Sarcoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Melanoma 6Lymphoma, Non-Hodgkin 6

Interventions

Carboplatin 7Pemetrexed 6osimertinib 5Drug Therapy 5tislelizumab 3anlotinib 3aflutinib 3Radiotherapy 3Radiosurgery 3Paclitaxel 3Cisplatin 3toripalimab 2pembrolizumab 2camrelizumab 2apatinib 2Surgical Procedures, Operative 2S 1 (combination) 2HM781-36B 2Chemotherapy, Adjuvant 2Chemoradiotherapy 2trilaciclib 1surufatinib 1sintilimab 1rezivertinib 1lenvatinib 1icotinib 1famitinib 1envafolimab 1dacomitinib 1cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × NSCLC × Drug Therapy × Clear all
NCT06738160 2026-03-20

The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer

Fudan University

Phase 2 Recruiting
27 enrolled
Thoracic

NSCLC

NCT07134413 2025-08-21

QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC

Guangdong Association of Clinical Trials

Phase 2 Not yet recruiting
77 enrolled
Thoracic

NSCLC

NCT06746870 2024-12-24

A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 2 Not yet recruiting
148 enrolled
BreastThoracic

NSCLC

NCT06479759 2024-06-28

ACCLAIM

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Recruiting
50 enrolled
Thoracic

NSCLC

NCT05286957 2023-03-17

Seagull

The First Affiliated Hospital of Zhengzhou University

Phase 2 Recruiting
60 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡